Teratogenicity of Drugs Most Commonly Used in Pregnancy
Project Number1R01HD046595-01A1
Contact PI/Project LeaderMITCHELL, ALLEN A
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Acetaminophen, aspirin, ibuprofen, and amoxicillin are among the most commonly used drugs during pregnancy, but the safety of these medications with respect to birth defects is not established. Given the wide use of these drugs, even a small increase in the risk of birth defects may have considerable clinical and public health implications. We propose to evaluate the association between these drugs and 1) specific malformations previously hypothesized to be associated with each of them, and 2) specific malformations that occur most commonly in the general population. In addition, we propose to evaluate other commonly used medications by systematically screening each exposure in relation to the risk of specific malformations. These goals can be achieved at relatively modest cost by taking advantage of a large existing ongoing multicenter case-control surveillance program of birth defects in North America, the Slone Epidemiology Center Birth Defects Study (BDS). The BDS involves approximately 95 institutions in four metropolitan areas (Boston, Philadelphia, Toronto, and San Diego), and for over 25 years has interviewed over 20,000 mothers of malformed infants and over 4,000 mothers of non-malformed infants. The BDS identifies infants with a wide range of malformations within 5 months after birth at tertiary and birth hospitals, and within 6 months of delivery, study nurses interview mothers about demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking and alcohol consumption; and dietary intake. The study has discovered likely teratogenic effects that have subsequently been confirmed by others (e.g., salycilates in relation to gastroschisis). In the proposed analyses, we will estimate odds ratios and 95% confidence intervals using logistic regression, and results will be adjusted for potential confounders. Findings will test hypotheses about some drugs and provide leads for further research for others; both objectives seek to improve our understanding of risks associated with drugs commonly used by pregnant women.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
acetaminophenaspirincleft palateclinical researchcomputer data analysiscomputer program /softwarecongenital cardiovascular disordercongenital nervous system disordercongenital reproductive system disordercongenital skeletal disorderembryo /fetus drug adverse effectgestational agehuman datahuman pregnant subjectibuprofenpenicillinspregnancypregnancy disorder chemotherapyself medicationstatistics /biometryteratogens
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
01-December-2004
Project End Date
30-November-2007
Budget Start Date
01-December-2004
Budget End Date
30-November-2005
Project Funding Information for 2005
Total Funding
$279,306
Direct Costs
$225,000
Indirect Costs
$54,306
Year
Funding IC
FY Total Cost by IC
2005
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$279,306
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01HD046595-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01HD046595-01A1
Patents
No Patents information available for 1R01HD046595-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01HD046595-01A1
Clinical Studies
No Clinical Studies information available for 1R01HD046595-01A1
News and More
Related News Releases
No news release information available for 1R01HD046595-01A1
History
No Historical information available for 1R01HD046595-01A1
Similar Projects
No Similar Projects information available for 1R01HD046595-01A1